New Stock Offerings - The tender offer for Shangwei New Materials (688585) is open from September 29, 2025, to October 28, 2025[1] - Zitian Tui (300280) is in the delisting adjustment period with only 2 trading days remaining until the last trading day[1] Market Alerts - Kesi Technology (688788) and Pinming Technology (688109) have recent announcements but no specific details provided[1] - Magu Technology (688448) is experiencing severe abnormal fluctuations[1] Trading Updates - Multiple companies including Dongjing (002199) and Guosheng Jinkong (002670) have announcements dated October 9, 2025, indicating ongoing trading activities[1] - Companies like Hunan Yuneng (301358) and Wanrun New Energy (688275) have announcements from October 1, 2025, indicating recent trading updates[1] Financial Disclosures - Several companies have disclosed their financial information, with specific announcements linked to their respective stock codes[1] - The report includes links to detailed announcements for various companies, providing transparency in their financial activities[1]

江苏丰山集团股份有限公司 关于可转债转股结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计转股情况：自"丰山转债"2023 年 1 月 3 日进入转股期，截至 2025 年 9 月 30 日，累计已有 417,950 张"丰山转债"转为公司股份，累计转股 金额 41,795,000 元，累计转股股数 3,043,406 股，累计转股股数占"丰山转债" 转股前公司已发行股份总额 162,293,880 股的 1.88%。 未转股可转债情况：截至 2025 年 9 月 30 日，尚未转股的"丰山转债" 金额为人民币 458,205,000 元，占"丰山转债"发行总额的 91.64%。 本季度转股情况：本季度，"丰山转债"转股金额为 850,000 元，因转 股形成的股份数量为 61,890 股。 一、可转债发行上市概况 | 证券代码：603810 | 证券简称：丰山集团 | 公告编号：2025-066 | | --- | --- | --- | | 转债代码：113649 | 转债简称：丰山 ...

每经记者｜朱成祥 每经编辑｜张海妮 丨 2025年10月9日 星期四 丨 NO.3 中国科学院金属研究所固态电池研究取得突破 近日，中国科学院金属研究所称，该所科研团队在固态锂电池领域取得突破，为解决固态电池界面阻抗 大、离子传输效率低的关键难题提供了新路径。该研究成果已于近日发表在国际学术期刊《先进材料》 上。固态锂电池因其高安全性和高能量密度，被视为下一代储能技术的重要发展方向。然而，传统固态 电池中电极与电解质之间的"固—固"界面接触不良，导致离子传输阻力大、效率低，严重制约其实际应 用。此项研究为发展高性能、高安全性固态电池提供了新的材料设计思路与研究范式。 点评：中国科学院金属所的此项突破，通过分子层面的精巧设计，巧妙地攻克了固态电池固有的界面难 题。这种"一体化"新材料不仅大幅提升了离子传输效率与能量密度，更展现出优异的柔韧性，为下一代 高安全、高性能储能电池的实用化铺平了道路，具有重要的科学价值和产业前景。 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自 担。 点评：杉杉股份控制权变更，标志着"船王"任元林携资本入主，终结了创始人离世后的家族纷争。此次 重整引入 ...

Group 1 - The Hong Kong stock market has shown positive performance with notable gains in technology-related companies such as Alibaba, Kuaishou, and SMIC, leading to increased expectations for the A-share market post-holiday [1] - 20 companies have announced share reduction plans, with 9 of them being new reduction plans, including Zhangjiang Hi-Tech, Zhejiang Wenlian, RunDa Medical, and Suotong Development [2] - Zhangjiang Hi-Tech plans to reduce its shares by up to 15,486,895 shares, not exceeding 1% of the total shares, within three months after the announcement [2] Group 2 - Lin'an Xinjing intends to reduce up to 23,746,800 shares, which is 1.60% of the total share capital, with specific limits for different trading methods [4] - RunDa Medical's shareholders, Zhu Wenyi and Liu Hui, plan to reduce their holdings by up to 10,540,000 shares and 7,460,000 shares respectively, representing 1.75% and 1.24% of the total shares [10] - Three companies have issued delisting risk warnings, including ST Dongshi, ST Suwu, and ST Zhengping, indicating potential risks of stock delisting due to low share prices [12] Group 3 - Eight companies have reported abnormal stock trading fluctuations, including Shida Shenghua, Pinming Technology, and Fengshan Group, which have issued announcements regarding these trading anomalies [12]

Key Points - Fengshan Group clarified that its sales do not involve solid-state battery electrolyte materials [1] - Zhiwei Co., Ltd. plans to invest approximately 1.5 billion yuan in the construction of high-end cast steel pump and valve components manufacturing project [1] - Tianyong Intelligent won a bid for a 58.8 million yuan DHE high-efficiency platform production line engine assembly line project [1] - Hanwei Technology intends to sell 65% of its stake in Hanwei Zhiyuan [1] - Huaxin Environmental plans to repurchase shares worth between 40 million to 80 million yuan [1] - Xin Nuo Wei is planning to issue E-shares and list on the Hong Kong Stock Exchange [1] - Shareholders of Run Da Medical, Zhu Wenyi and Liu Hui, plan to reduce their holdings by no more than 2.99% [1] - Feng Assistant intends to raise no more than 984 million yuan through a private placement to actual controllers [1] - Jiaotong Sino's chairman Li Wei has been placed under detention [1] Investment Projects - Nong Shang Environment's subsidiary plans to invest in the construction of intelligent computing center infrastructure [1] - Sai En Si (Fujian Longli Chemical) plans to invest no more than 300 million yuan in the expansion of the selection agent project [1] - Bin Hua Co. intends to invest 1.421 billion yuan in the construction of an integrated source network load storage project [1] Contracts and Acquisitions - Zhong Wu Drone signed a major contract worth 615 million yuan [1] - Xin Nuo Wei plans to acquire a 29% stake in Ju Shi Bio [1] - Huaheng Biological submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [1] - Kete Power plans to issue shares overseas (H-shares) and apply for listing on the Hong Kong Stock Exchange [1]

Core Viewpoint - The company, Fengshan Group, clarifies that its main business remains focused on the production, research, and sales of raw medicines and formulations, despite media reports linking it to the "solid-state battery" concept [1] Business Operations - The company primarily sells lithium-ion electrolytes, with sodium-ion electrolytes making up a very small portion of sales, accounting for only 0.01% of the consolidated revenue by mid-2025 [1] - The collaboration with Tsinghua University, led by Professor Zhang Qiang, is at an early research and development stage, with a small contract amount and a long project timeline extending to December 31, 2028 [1] Research and Development - The research project commissioned by the company is not the same as the significant research results recently published by Professor Zhang's team [1] - There is considerable uncertainty regarding the future research outcomes and their commercialization [1]

Core Viewpoint - Fengshan Group (603810.SH) clarifies that its main business remains focused on the production, research, and sales of raw medicines and formulations, despite media reports linking the company to the "solid-state battery" concept [1] Business Operations - The company emphasizes that its main operations have not changed, and its subsidiary Fengshan Quannuo primarily sells lithium-ion electrolytes, with sodium-ion electrolytes accounting for a relatively small proportion of sales [1] - As of the first half of 2025, sodium-ion electrolyte sales are projected to represent only 0.01% of the company's consolidated revenue [1] Research and Development - The recent important research results published by Professor Zhang Qiang's team from Tsinghua University are not related to the research and development project commissioned by the company [1] - The collaboration with Tsinghua University is still in the preliminary research and development phase, with a small contract amount, and the technical development project is expected to last until December 31, 2028, indicating significant uncertainty regarding future research outcomes and commercialization [1]

Core Viewpoint - Fengshan Group (603810.SH) clarifies that its main business remains focused on the production, research, and sales of raw medicines and formulations, despite media reports linking the company to the "solid-state battery" concept [1] Business Operations - The company’s main business has not changed, and its subsidiary Fengshan Quannuo primarily sells lithium-ion electrolytes, with sodium-ion electrolytes accounting for a relatively small proportion of sales [1] - As of the first half of 2025, sodium-ion electrolyte sales are expected to represent only 0.01% of the company’s consolidated revenue [1] Research and Development - The important research results published by Professor Zhang Qiang's team from Tsinghua University are not related to the research and development project commissioned by the company [1] - The collaboration with Tsinghua University is still in the preliminary research and development phase, with a small contract amount, and the technical development project is scheduled to last until December 31, 2028, indicating significant uncertainty regarding future research outcomes and commercialization [1]

Core Viewpoint - The company, Fengshan Group (603810.SH), clarifies that its main business remains focused on the production, research, and sales of raw medicines and formulations, despite recent media reports linking it to the "solid-state battery" concept [1] Business Operations - The company’s main business has not changed, and its subsidiary, Fengshan Quannuo, primarily sells lithium-ion electrolytes, with sodium-ion electrolytes making up a relatively small portion of sales [1] - As of the first half of 2025, sodium-ion electrolyte sales are expected to account for only 0.01% of the company's consolidated revenue [1] Research and Development - The important research results published by Professor Zhang Qiang's team from Tsinghua University are not related to the research and development project commissioned by the company [1] - The collaboration with Tsinghua University is still in the preliminary research and development phase, with a small contract amount, and the technical development project is scheduled to last until December 31, 2028 [1] - There is significant uncertainty regarding the subsequent research outcomes and their commercialization [1]

Core Viewpoint - The company clarifies that its main business remains focused on the production, research, and sales of raw medicines and formulations, despite media reports linking it to the "solid-state battery" concept [1] Business Operations - The company's main business has not changed, and its subsidiary, Fengshan Quannuo, primarily sells lithium-ion electrolytes, with sodium-ion electrolytes making up a relatively small portion of sales [1] - As of the first half of 2025, sodium-ion electrolyte sales are expected to account for only 0.01% of the company's consolidated revenue [1] Research and Development - The important research results published by Professor Zhang Qiang's team from Tsinghua University are not related to the company's commissioned research and development project [1] - The collaboration with Tsinghua University is currently in the preliminary research and development phase, with a small contract amount, and the technology development project is scheduled to last until December 31, 2028 [1] - There is significant uncertainty regarding the subsequent research outcomes and their commercialization [1]